Anti-inflammatory

Clinically approved

Nonsteroidal anti-inflammatory drugs

Main article: Nonsteroidal anti-inflammatory drug

NSAIDs alleviate pain by counteracting the cyclooxygenase (COX) enzyme involved in pain mechanisms.

Some common examples of NSAIDs are aspirin, ibuprofen, and naproxen. Selective COX-2 inhibitors, such as celecoxib, block the enzymatic conversion of arachidonic acid into prostaglandin, inhibiting inflammation and pain.

Analgesics commonly associated with anti-inflammatory drugs, such as paracetamol (acetaminophen), have no peripheral anti-inflammatory effects. High, short-term doses of NSAIDs may become toxic, causing gastric erosions, stomach ulcers, internal bleeding, hepatotoxicity, or kidney disease.

The risk of death as a result of GI bleeding caused by the use of NSAIDs is 1 in 12,000 for adults aged 16–45. The risk increases almost twentyfold for those over 75. Apart from aspirin, frequent or high doses of prescription and over-the-counter NSAIDs may increase the risk of heart attack and stroke.

Corticosteroids

Corticosteroids, specifically glucocorticoids or glucocorticoid receptor agonists, are powerful anti-inflammatory agents, but they are also powerful immunosuppressants and are associated with various toxicities, which constrain their use.

Antileukotrienes

Antileukotrienes are anti-inflammatory agents which function as leukotriene-related enzyme inhibitors (arachidonate 5-lipoxygenase) or leukotriene receptor antagonists (cysteinyl leukotriene receptors), and consequently oppose the function of these inflammatory mediators. Although they are not used for analgesic benefits, they are used to manage diseases related to inflammation of the lungs, such as asthma, as well as being used for sinus inflammation in allergic rhinitis. Examples include montelukast and zileuton.

Monoclonal antibodies

Monoclonal antibodies, for instance against pro-inflammatory cytokines like interleukin-6 (anti-interleukin-6) and tumor necrosis factor α (TNFα) (TNF inhibitors), are approved and used in the treatment autoimmune diseases and other inflammatory conditions.

Colchicine

Colchicine is an anti-inflammatory agent that disrupts the function of cytoskeletal by inhibiting microtubule polymerization, doing so prevents the activation, degranulation and migration of neutrophils. Colchicine is mostly used in treatment of acute gout. It can also be used for treating familial Mediterranean fever and pericarditis.

Investigational and off-label

Omega-3 fatty acids

Omega-3 fatty acids may have anti-inflammatory effects, although clinical studies show that possible effects have been inconsistent, requiring further research. A 2017 review indicated that omega-3 fatty acids may benefit rheumatoid arthritis, although another analysis indicated no consistent effect. There is no good evidence that use of omega-3 fatty acids provides relief in retinal inflammation or in dry eye syndrome.

''N''-Acetylcysteine

N-Acetylcysteine (NAC) has been found to possess anti-inflammatory effects and has been clinically studied in the treatment of conditions involving inflammation.

Melatonin

A 2021 review reported that melatonin has anti-inflammatory effects. Found to reduce levels of several pro-inflammatory cytokines, it remains under preliminary research for its potential to treat inflammation.

Serotonin 5-HT_2A receptor agonists

Serotonin 5-HT2A receptor agonists, including serotonergic psychedelics, are under preliminary research as possible anti-inflammatory agents. The anti-inflammatory effects of some psychedelics, like DOI and psilocybin, have been found to occur at much lower doses than those at which they produce their hallucinogenic effects. Serotonin 5-HT2A receptor agonists with anti-inflammatory properties are under clinical investigation as possible treatments for inflammatory disorders.

Tetracyclic antibiotics

The tetracycline antibiotics minocycline and doxycycline have been found to have anti-inflammatory and immunomodulatory effects. Minocycline has been found to have some clinical benefit in people with treatment-resistant depression with inflammation but not in those without inflammation.

Macrolide antibiotics

The macrolide antibiotic azithromycin is known to have anti-inflammatory and immunomodulatory properties. It is said to be established and effective for certain inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease (COPD). Azithromycin is also being assessed for potential treatment of other chronic inflammatory disorders.

Statins

Statins like atorvastatin and simvastatin are used to treat inflammatory conditions like rheumatoid arthritis and chronic kidney disease. Statins may be useful for treating other inflammatory conditions, like uveitis, depression, and possibly neuropsychiatric disorders. However, higher-quality evidence of statins for treatment of neuropsychiatric and other conditions is still needed.

Curcumin

A 2019 systematic review and meta-analysis found that curcumin or turmeric did not significantly decrease several circulating inflammatory markers in people with various chronic inflammatory diseases. Major problems of assessing curcumin in human studies are its unknown fate and properties after digestion, and its poor bioavailability.

References

References

1. (1 May 2023). "StatPearls [Internet]". StatPearls Publishing.
2. (November 2010). "Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity". Expert Review of Clinical Pharmacology.
3. (28 February 2024). "COX inhibitors". StatPearls, US National Library of Medicine.
4. (11 January 2024). "Acetaminophen". StatPearls, US National Library of Medicine.
5. "Table 7". Bandolier.
6. (January 2011). "Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis". BMJ.
7. (April 2020). "New insights into the novel anti-inflammatory mode of action of glucocorticoids". Immunopharmacology and Immunotoxicology.
8. (2019). "Fighting the Fire: Mechanisms of Inflammatory Gene Regulation by the Glucocorticoid Receptor". Frontiers in Immunology.
9. (September 2013). "Antileukotriene agents for the treatment of lung disease". American Journal of Respiratory and Critical Care Medicine.
10. (October 2025). "The Spectrum of Allergic Rhinitis: Risk Factors and their Clinical Relevance". Recent Advances in Inflammation & Allergy Drug Discovery.
11. (April 2016). "Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases". International Immunology.
12. (2017). "Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics". Frontiers in Pharmacology.
13. (April 2019). "Targets of monoclonal antibodies for immunological diseases". Archives of Pharmacal Research.
14. (March 2016). "Management of Gout [Internet]". Agency for Healthcare Research and Quality (US).
15. (April 2022). "Colchicine (Myinfla): CADTH Reimbursement Review: Therapeutic area: Atherothrombotic events in coronary artery disease [Internet]". Canadian Agency for Drugs and Technologies in Health.
16. (17 December 2024). "Omega-3 Fatty Acids: Fact Sheet for Health Professionals". Office of Dietary Supplements, US National Institutes of Health.
17. (October 2017). "Omega-3 fatty acids and inflammatory processes: from molecules to man". Biochemical Society Transactions.
18. (July 2024). "Anti-Inflammatory and Anti-Oxidant Properties of N-Acetylcysteine: A Fresh Perspective". Journal of Clinical Medicine.
19. (March 2021). "Anti-inflammatory effects of melatonin: A systematic review and meta-analysis of clinical trials". Brain, Behavior, and Immunity.
20. (February 2017). "Psychedelics as Medicines: An Emerging New Paradigm". Clinical Pharmacology and Therapeutics.
21. (November 2022). "Psychedelics as potent anti-inflammatory therapeutics". Neuropharmacology.
22. (July 2022). "From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders". Journal of Neurochemistry.
23. (December 2020). "Immunotherapy of Autoimmune Diseases with Nonantibiotic Properties of Tetracyclines". Immune Network.
24. (2021). "Minocycline and Doxycycline: More Than Antibiotics". Current Molecular Pharmacology.
25. (September 2023). "Role of Minocycline as an Adjunct Neuroinflammatory Modulator in Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials". The Primary Care Companion for CNS Disorders.
26. (December 2020). "Azithromycin: The First Broad-spectrum Therapeutic". European Journal of Medicinal Chemistry.
27. (December 2021). "The immunomodulatory effects of macrolide antibiotics in respiratory disease". Pulmonary Pharmacology & Therapeutics.
28. (November 2019). "Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis". The European Respiratory Journal.
29. (July 2012). "COPD exacerbations: causes, prevention, and treatment". The Medical Clinics of North America.
30. (August 2014). "Azithromycin: mechanisms of action and their relevance for clinical applications". Pharmacology & Therapeutics.
31. (April 2012). "Azithromycin in periodontal treatment: more than an antibiotic". Journal of Periodontal Research.
32. (March 2018). "The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials". Autoimmunity Reviews.
33. (2022). "Statins Have an Anti-Inflammation in CKD Patients: A Meta-Analysis of Randomized Trials". BioMed Research International.
34. (2017). "Statins as anti-inflammatory agents: A potential therapeutic role in sight-threatening non-infectious uveitis". Porto Biomedical Journal.
35. (2021). "Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials". PLOS ONE.
36. (January 2020). "Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials". Journal of Neurology, Neurosurgery, and Psychiatry.
37. (December 2021). "Update on Statin Treatment in Patients with Neuropsychiatric Disorders". Life.
38. (December 2022). "Anti-inflammatory medications for the treatment of mental disorders: A scoping review". Brain, Behavior, & Immunity - Health.
39. (November 2020). "Statins in the treatment of depression: Hype or hope?". Pharmacology & Therapeutics.
40. (August 2019). "Oral turmeric/curcumin effects on inflammatory markers in chronic inflammatory diseases: A systematic review and meta-analysis of randomized controlled trials". Pharmacological Research.
41. (September 2016). "Oral bioavailability of curcumin: problems and advancements". Journal of Drug Targeting.
42. (March 2023). "Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?". ACS Omega.
43. (May 2024). "Clinical trials on curcumin in relation to its bioavailability and effect on malignant diseases: critical analysis". Naunyn-Schmiedeberg's Archives of Pharmacology.